About Type 2 Inflammation – Atopic Dermatitis
-(2).png/jcr:content/science%20hero%20(1)%20(2).png)
The Continuous burden of Atopic Dermatitis can have far-reaching Impact
The burden of inadequately controlled atopic dermatitis may become chronic, or even cumulative, impacting patients throughout their lives1,2
~70 - 80% of atopic dermatitis patients develop additional type 2 inflammatory diseases, such as asthma or allergic rhinitis, which correlate with atopic dermatitis severity5,6
*The age of children included in the Eczema Society of Canada Atopic Dermatitis Quality of Life Report survey ranged from 0 to 18 years
~70 - 80% of atopic dermatitis patients develop additional type 2 inflammatory diseases, such as asthma or allergic rhinitis, which correlate with atopic dermatitis severity5,6
* The age of children included in the Eczema Society of Canada Atopic Dermatitis Quality of Life Report survey ranged from 0 to 18 years
~70 - 80% of atopic dermatitis patients develop additional type 2 inflammatory diseases, such as asthma or allergic rhinitis, which correlate with atopic dermatitis severity5,6
* The age of children included in the Eczema Society of Canada Atopic Dermatitis Quality of Life Report survey ranged from 0 to 18 years
Around 3 in 5 adult Moderate-to-Severe Atopic Dermatitis patients are Inadequately controlled despite treatment1*
.png)
A chronic, inadequately controlled disease driven by persistent underlying inflammation7,8
.jpg)
Patients may experience intensified disease activity for 30–50% of the year2
.jpg)
Current treatment paradigm (OCS/ immunosuppressants) primarily addresses disease manifestation using a reactive, episodic approach9
Length of treatment with systemic steroids and other immunosuppressants is limited by common side effects and chance of rebounds11
Continuous treatment of underlying Inflammation is warranted for Long-term disease control10
A more sustainable treatment paradigm proactively targets the persistent underlying inflammation with a safety profile that allows for continuous treatment10-12
Adequately controlled disease with long-term improvements in signs, symptoms, and quality of life.
Dysregulation of the Type 2 Immune Response pathway leads to Underlying Type 2 Inflammation in Atopic Dermatitis and other Type 2 Inflammatory diseases*
Inflammatory Pathway | Type 1 | Type 2 | Type 3 |
| Primary immune cells1-3 |  |  |  |
| Key cytokines1-4 |  |  |  |
| Associated intracellular signaling pathway4,5 |  | .jpg) | .jpg) |
| Natural defensive roles against:1,3,6 | Viral infection Intracellular bacterialinfection Cancer cells | Allergens Parasites | Extracellular bacteria Fungi |
| Associated diseases when dysregulated7-8 | Psoriasis Psoriatic arthritis | Atopic dermatitis Asthma CRSwNP | Psoriasis Psoriatic arthritis |
*Simplified depiction based on key published information; not meant to be exhaustive in nature.
In Atopic Dermatitis, Type 2 Inflammation is always present throughout the body,even in nonlesional or normal-looking skin1–3
- Dysregulation of the type 2 immune response and increased IL-4 and IL-13 signaling drives and perpetuates type 2 inflammation, which contributes to clinical disease features in atopic dermatitis and other type 2 inflammatory diseases3-5
-
IL-4 and IL-13 are produced by various cell types such as Th2 and ILC2 cells in response to increased signaling through the IL-4Rα present on those cells6-8
Nonlesional skin is not normal skin
In atopic dermatitis, subclinical inflammation is also present in nonlesional skin1–3
